Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Paxman ABPXMBF 76 EV-to-EBITDA is 32.91 as of Jul. 22, 2026, which is 20% above its 10-year median of 27.46. GuruFocus rates PXMBF with a GF Score™ of 76/100 and a GF Value™ of $4.73. The stock has 3 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Paxman AB ranks worse than 82.16% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Paxman AB's enterprise value is $102.13 Mil.
Paxman AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $3.10 Mil. Therefore, Paxman AB's EV-to-EBITDA for today is 32.91.
The historical rank and industry rank for Paxman AB's EV-to-EBITDA or its related term are showing as below:
PXMBF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7584.46 Med: 27.46 Max: 2179.24
Current: 33.54
During the past 9 years, the highest EV-to-EBITDA of Paxman AB was 2179.24. The lowest was -7584.46. And the median was 27.46.
PXMBF's EV-to-EBITDA is ranked worse than 82.16% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 13.93
vs PXMBF: 33.54
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Paxman AB (OTCPK:PXMBF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Paxman AB's share price for today is $3.50.
Paxman AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.052.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Paxman AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Paxman AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paxman AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paxman AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Paxman AB's EV-to-EBITDA falls into.
Paxman AB's current Enterprise Value is $102.13 Mil.
Paxman AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paxman AB (PXMBF) has a EV-to-EBITDA of 32.91 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Paxman AB. This is 20% above median its historical median of 27.46. According to the industry distribution chart, Paxman AB ranks #419 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 82.2%.
Is Paxman AB's EV-to-EBITDA too high?
Paxman AB's current EV-to-EBITDA of 32.91 is 20% above median its 10-year median of 27.46. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.93. Paxman AB's value of 32.91 is 136.3% above this industry median. Based on the distribution chart, Paxman AB ranks #419 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Paxman AB has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Paxman AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Paxman AB ranks #419 out of 510 companies for EV-to-EBITDA. This places Paxman AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.93. Paxman AB's value of 32.91 is 136.3% above this benchmark. While the company's 10-year median is 27.46 vs. the industry median of 13.93, Paxman AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.93, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paxman AB's current EV-to-EBITDA of 32.91 is 136.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Paxman AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paxman AB's current EV-to-EBITDA is 32.91, which is 20% above median its own 10-year median of 27.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paxman AB stock overvalued right now?
Paxman AB (PXMBF) has a current EV-to-EBITDA of 32.91. The stock's GF Value™ is $4.73, compared to a current price of $3.50 — trading 26% below its estimated fair value. The current EV-to-EBITDA is 32.91, which is 20% above median its 10-year median of 27.46 and 136.3% above the Medical Devices & Instruments industry median of 13.93. Paxman AB's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Paxman AB (PXMBF), the current EV-to-EBITDA is 32.91 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paxman AB (PXMBF) Overvalued in 2026?
Based on GuruFocus' analysis, Paxman AB stock appears to be undervalued.
The current stock price of $3.50 is trading 26% below its estimated GF Value™ of $4.73.
Key valuation signals for PXMBF:
EV-to-EBITDA: 32.91 (20% above median its 10-year median of 27.46)
GF Value™: $4.73 vs. price of $3.50 (26% below fair value)
Industry Position: 136.3% above the Medical Devices & Instruments median (#419 of 510)
No single metric tells the full story. See the PXMBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paxman AB is a Sweden-based company engaged in the development of the PAXMAN Scalp Cooling System, which has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The portfolio includes both the Paxman and Digni Capsystems with several installations in hospitals, clinics, and treatment centres world-wide.
76GF Score
Get the complete analysis for PXMBF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PXMBF has been successfully added to your 
